Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 28;66(6):ezae413.
doi: 10.1093/ejcts/ezae413.

Association between warfarin use and thromboembolic events in patients post-Fontan operation: propensity-score overlap weighting analyses

Wakana Maki  1 , Shotaro Aso  2 , Ryo Inuzuka  3 , Hiroki Matsui  4 , Kiyohide Fushimi  5 , Hideo Yasunaga  1
Affiliations

Association between warfarin use and thromboembolic events in patients post-Fontan operation: propensity-score overlap weighting analyses

Wakana Maki et al. Eur J Cardiothorac Surg. .

Abstract

Objectives: The appropriate antithrombotic regimen after a Fontan operation is yet to be elucidated. Hence, this study aimed to compare the incidence of thromboembolic events in patients with and without receiving warfarin for thromboprophylaxis in a large post-Fontan population.

Methods: This retrospective cohort study used data from the Diagnosis Procedure Combination database in Japan between April 2011 and March 2022. We identified all patients who underwent a Fontan operation and excluded those who were born before 2010, died during the hospitalization or received mechanical heart replacement. Propensity score overlap weighting was performed between patients discharged with warfarin (with or without aspirin) and the control group (only aspirin or neither aspirin nor warfarin). Cox and Fine-Gray hazards models compared thromboembolic and bleeding events.

Results: We identified 2007 eligible patients, including 1670 warfarin users and 337 non-users. The mean follow-up duration was 2.1 years. The crude proportions of thromboembolic events were 3.0% and 3.0% and those of bleeding events were 0.4% and 0.3% in the warfarin and control groups, respectively. There was no significant difference in thromboembolic events between the groups (sub-distribution hazard ratio: 0.77; 95% confidence interval 0.39-1.51; P = 0.45) or bleeding events (sub-distribution hazard ratio: 0.78; 95% confidence interval 0.09-7.03; P = 0.83).

Conclusions: Warfarin use at discharge after a Fontan operation may not be necessary for thromboembolism prophylaxis in paediatric patients, based on large-scale real-world data, with a mean postoperative follow-up duration of 2.1 years. There is room for further studies to reconsider routine warfarin use in patients post-Fontan operation.

Keywords: Bleeding events; Fontan procedure; Observational study; Thromboprophylaxis; Thrombosis; Warfarin.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1:
Figure 1:
Flow chart for participant selection.
Figure 2:
Figure 2:
Cumulative incidences of thromboembolic events requiring hospitalization in the overlap-weighted warfarin and control (non-warfarin) groups.
Figure 3:
Figure 3:
Cumulative incidences of bleeding events requiring hospitalization and any surgical procedures in the overlap-weighted warfarin and control (non-warfarin) groups.
See this image and copyright information in PMC

References

    1. Rychik J, Atz AM, Celermajer DS, Deal BJ, Gatzoulis MA, Gewillig MH. et al. ; American Heart Association Council on Cardiovascular Disease in the Young and Council on Cardiovascular and Stroke Nursing. Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the American Heart Association. Circulation 2019;140:e234–84. - PubMed
    1. Ankola AA, Anderson BR, Choudhury TA, Rochelson E, Corda R, Bacha EA. et al. Early thromboprophylaxis initiation is associated with reduced Fontan thromboses in the early postoperative period. Semin Thorac Cardiovasc Surg 2021;33:806–13. - PubMed
    1. Van Den Helm S, Sparks CN, Ignjatovic V, Monagle P, Attard C.. Increased risk for thromboembolism after Fontan surgery: considerations for thromboprophylaxis. Front Pediatr 2022;10:803408. - PMC - PubMed
    1. McCrindle B, Michelson A, Van Bergen AH, Horowitz ES, Sandoval JP, Justino H. et al. ; UNIVERSE Study Investigators. Thromboprophylaxis for children post‐Fontan procedure: insights from the UNIVERSE study. J Am Heart Assoc 2021;10:e021765. - PMC - PubMed
    1. McCrindle BW, Manlhiot C, Cochrane A, Roberts R, Hughes M, Szechtman B. et al. ; Fontan Anticoagulation Study Group. Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. J Am Coll Cardiol 2013;61:346–53. - PubMed

MeSH terms